DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned an average rating of “Moderate Buy” from the twenty-six research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nineteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $84.8333.

A number of research analysts recently issued reports on DXCM shares. Piper Sandler reiterated an “overweight” rating and set a $88.00 price objective (up from $75.00) on shares of DexCom in a research note on Monday. Canaccord Genuity Group set a $82.00 price objective on DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Barclays reiterated an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Bank of America cut their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, UBS Group set a $95.00 price objective on DexCom in a research note on Wednesday, June 10th.

DexCom Price Performance

NASDAQ DXCM opened at $73.16 on Wednesday. DexCom has a 52 week low of $54.11 and a 52 week high of $89.98. The firm has a market capitalization of $28.23 billion, a P/E ratio of 31.26, a PEG ratio of 1.16 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average price of $66.59 and a 200-day moving average price of $67.76.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. Equities research analysts anticipate that DexCom will post 2.58 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 40,994 shares of company stock valued at $2,919,022. 0.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Trust Co. of Vermont raised its holdings in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares in the last quarter. CVA Family Office LLC raised its holdings in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. raised its holdings in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.